ABSTRACT
The recommended treatment for hyposmia (clinically reduced sense of smell) is olfactory training using odors in containers that the patients smell twice a day for several weeks. Adherence to the olfactory training regimen is, however, generally low. We aimed to investigate if a new form of olfactory delivery via scented nasal inserts could enhance olfactory training adherence by allowing participants to be mobile while performing the training and thereby lower perceived intrusion in their everyday life, using a randomized controlled parallel-group design. Two groups of individuals with hyposmia underwent 8 weeks of olfactory training. One group (n=60) performed olfactory training using scented nasal inserts (nasal plugs that retain nasal patency) and one group (n=56) performed the standard care regiment currently recommended by the Swedish healthcare system. We assessed objective and subjective olfactory ability before and after olfactory training as well as adherence to training. While both groups significantly improved their objective and subjective olfactory abilities, training with nasal insert produced similar improvement as standard care in overall treatment outcome. However, there was a significantly greater increase in discrimination performance and lower dropout rate (6.7%) in the nasal insert compared to the standard care group (23.2%). Critically, the nasal insert group had a significantly higher adherence to the training regimen, i.e. fewer missed training sessions. In addition, they reported overall greater satisfaction with their treatment. These data suggest that olfactory training with nasal inserts could serve as a more effective form of treatment for hyposmia, due to patients improved adherence to protocol and increased tendency to finish their treatment regimen.
Competing Interest Statement
JNL receives financial compensation from Sulcus Consulting AB where NosaMed AB, the maker of the NosaPlug, is a client.
Clinical Trial
NCT06142565
Funding Statement
Funding was provided by grants awarded to JNL from the Knut and Alice Wallenberg Foundation (KAW 2018.0152), the Swedish Research Council (2021-06527), and a donation from Stiftelsen Bygg-Gota for Vetenskaplig forskning. The Nosa plugs were provided free of charged by Nosa Plug AB. The funders had no input on study design,
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority (Dnr: 2023-03779-01) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Upon journal acceptance, all raw data and analyses scripts will be available at the Open Science Framework (OSF).
https://osf.io/g6e53/?view_only=60e7df87bd8647a389630dfa55b6b527
